Marianne Isach, the new CEO of ATRYS after controversy for noted oncology

ATRYS Health-Bienzobas He suggested a re -view for him Dome After many media and oncologists, he condemned alleged pressure so that medications are not prescribed at high prices. Specifically, the company will replace the current CEO, Isabel Luzano Marian IshatCurrently, Managing Director of the Oncology Department. Consequently, not only facing the Caliphate stage, but ISach itself will have to do the problems that They surround the company since last March.

The appointment of the new CEO at the ATRY shareholder will be appointed, which will happen Next June. This will be after that, at the summer doors, when more changes reach the company. This Santiago de TorresThat was now Health CEO, He will become a non -executive president for himself.

This was announced by the company through a statement, and it has detailed that ATRES has reached a growth of up to 112 percent (a total of 57.2 million euros) From income in the first quarter of 2025. All this is in the middle of last March scandal, where the company became in the spotlight.

“Generations Relief”

In the same statement, which was able to reach Medical writingATRES indicates the cause of these changes. Marian Isach, the current administrative director of the Oncology Department, is part of The caliphate of generations and the decline plan The company says: “ATRES was launched in March 2024, and the company’s commitment to promoting internal talent reflects,” the company says.

Thus, ISach also explains that I have worked alongside in recent months with Isabelle Luzano, who will now continue, such as Torres, “Associated with the company”. However, Atrys did not specify what the position of the CEO will be.

Isach file

As it explains, Atrys, ISACH Extensive experience in the sector. The new guidance, which has so far been the managing director of the division division oncology (Since he assumed in 2022, he has more than 27 years of traveling in the field. In particular, he has held business administration positions and developing them in the sector, and 25 of them specialize in oncology.

Athris case

The company came out on March 18, when several media chanted some of them Simidant pressures for oncologists Do not prescribe medications at high prices. At that time, many healthy (public and private) actors talked about the matter.

Specifically, and Spanish Association for Medical Oncology (SEOM) He said that it is concerned “seriously to the group of medical oncologists who are practicing specialization in Spain.”

For its part, He raised his self -defending He explained that the final decision for The prescription is “the doctor’s decision always”. He also pointed out that “” does not get an additional benefit depending on the type of recommendation you issue “and that your reports” are based on professional and measurable standards, and it is advised whether the treatment is indicated or not for the patient. “

Minister of Health, Monica GarciaAlso talk about it. “Oncology in companies is separately so as not to prescribe some treatments not health, this is the work. For this reason we defend public health as doctors decide according to scientific evidence, and not according to economic benefits. Health has not been negotiated“.

And, as for the private sector, Fundación IdisIn charge of compensating multiple companies of private health (among them, ATRES), it is submitted to this newspaper that he believes freely professional in achieving the best care and the best diagnostic and treatment option for patients.

In this sense, Edis said: ” The presence of oncology committeesIn both public health and health, to assess treatments and their effectiveness, which is usual and is implemented in accordance with good occupational practical standards, to provide each patient with optimal treatment, based on clinical standards and treatment evidence. ”